Fernando Monteiro Aarestrup
Research Subjects
Research Interests
Fernando Monteiro Aarestrup has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Dirceu Solé
Universidade Federal de São Paulo, Brazil
4 shared publications Matheus Fonseca Aarestrup
Allergy and Immunology Department, Suprema Medical School and Health Science, Hospital Maternidade Therezinha de Jesus, Juiz de Fora, Brazil
4 shared publicationsPaula Fonseca Aarestrup
Albert Einstein Hospital, São Paulo, Brazil
4 shared publicationsAkinori Cardozo Nagato
Physiology Department, Federal University of Juiz de Fora, Juiz de Fora, Brazil
3 shared publications- Akinori Cardozo Nagato
Laboratory of Biophysics, Morphophysiology and Inflammation, Department of Biophysics and Physiology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil
3 shared publications - Beatriz Julião Vieira Aarestrup
Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Brasil
3 shared publications
Latest Publications
- Open Access
- 14 February 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 5 (3) , 100670
Monitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform
- 14 February 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 5 (3) , 100670
Open AccessMonitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 59, e15168
Surgical induction model of femoral defect in Wistar rats for bone repair histology
The creation of bone lesions using a well-established surgical technique is essential for obtaining histological images in experimental models that aim to study the pathophysiology of bone repair. In this study, we report the steps of a surgical method to induce bone defects in Wistar rats, providing a basis for experimental studies requiring precision in these lesions, especially for future experimental tests and subsequent histological analysis. The animal model remains an important alternative for investigating the inflammatory process and bone regeneration. The model consists of creating experimental, non-critical surgical bone defects in the femurs of Wistar rats (Rattus norvegicus, 90 days old, weighing between 250-300 g) using a 2-mm spherical drill and a low-speed motor. The present report includes reproducible information on the selection of the animals and the materials needed to perform anesthesia and surgery to induce bone defects. It also provides details on post-surgical care, sample collection, and preparation of samples for histological processing. The steps presented here can significantly increase the accuracy of lesion creation and allow for more precise results in the analysis of bone architecture and repair.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 59, e15168
Open AccessSurgical induction model of femoral defect in Wistar rats for bone repair histology
The creation of bone lesions using a well-established surgical technique is essential for obtaining histological images in experimental models that aim to study the pathophysiology of bone repair. In this study, we report the steps of a surgical method to induce bone defects in Wistar rats, providing a basis for experimental studies requiring precision in these lesions, especially for future experimental tests and subsequent histological analysis. The animal model remains an important alternative for investigating the inflammatory process and bone regeneration. The model consists of creating experimental, non-critical surgical bone defects in the femurs of Wistar rats (Rattus norvegicus, 90 days old, weighing between 250-300 g) using a 2-mm spherical drill and a low-speed motor. The present report includes reproducible information on the selection of the animals and the materials needed to perform anesthesia and surgery to induce bone defects. It also provides details on post-surgical care, sample collection, and preparation of samples for histological processing. The steps presented here can significantly increase the accuracy of lesion creation and allow for more precise results in the analysis of bone architecture and repair.
- Open Access
- 28 August 2025
- Published by Scientific Electronic Archives in Scientific Electronic Archives
- Vol. 18 (5)
Attenuation of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice by Licochalcone A
Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the central nervous system (CNS) that affects more than 2.5 million people worldwide. The experimental autoimmune encephalomyelitis (EAE) is an appropriate and a well-establish model for studying the pathogenesis of MS. Licochalcone A (LicoA) is a chalcone obtained from the roots of Glycyrrhiza inflata (Fabaceae) that has in vitro immunomodulatory effects. EAE was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein and we have investigated the treatment of LicoA in this animal model. LicoA was isolated from G. inflata and was orally administered during the development of EAE. The capacity of absorption and distribution of LicoA, after gavage, to the brain was performed by HPLC. The clinical course and body weight were performed daily, cytokines (ELISA) and oxygen radicals production (NO and H2O2) were investigated. The CNS sections were stained by hematoxylin and eosin. After the treatment, by HPLC, at the first time, we analyzed the penetration between tissue/plasma, and our results showed that LicoA was present in serum and reached the mice brain with a good distribution. LicoA reduced clinical score and severity of EAE-mice, as well as inhibited H2O2, NO, TNF-α, IFN-γ and, mainly, IL-17 production. Histopathological analysis confirmed that LicoA treatment significantly reduced the numbers of inflammatory infiltrates and attenuates neurological damages in the CNS. These findings demonstrate that the oral treatment of LicoA significantly ameliorated the inflammatory signs associated with EAE, since it is effective at reducing both disease onset and severity.
- 28 August 2025
- Published by Scientific Electronic Archives in Scientific Electronic Archives
- Vol. 18 (5)
Open AccessAttenuation of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice by Licochalcone A
Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the central nervous system (CNS) that affects more than 2.5 million people worldwide. The experimental autoimmune encephalomyelitis (EAE) is an appropriate and a well-establish model for studying the pathogenesis of MS. Licochalcone A (LicoA) is a chalcone obtained from the roots of Glycyrrhiza inflata (Fabaceae) that has in vitro immunomodulatory effects. EAE was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein and we have investigated the treatment of LicoA in this animal model. LicoA was isolated from G. inflata and was orally administered during the development of EAE. The capacity of absorption and distribution of LicoA, after gavage, to the brain was performed by HPLC. The clinical course and body weight were performed daily, cytokines (ELISA) and oxygen radicals production (NO and H2O2) were investigated. The CNS sections were stained by hematoxylin and eosin. After the treatment, by HPLC, at the first time, we analyzed the penetration between tissue/plasma, and our results showed that LicoA was present in serum and reached the mice brain with a good distribution. LicoA reduced clinical score and severity of EAE-mice, as well as inhibited H2O2, NO, TNF-α, IFN-γ and, mainly, IL-17 production. Histopathological analysis confirmed that LicoA treatment significantly reduced the numbers of inflammatory infiltrates and attenuates neurological damages in the CNS. These findings demonstrate that the oral treatment of LicoA significantly ameliorated the inflammatory signs associated with EAE, since it is effective at reducing both disease onset and severity.
- Open Access
- 12 May 2025
- Published by Elsevier in World Allergy Organization Journal
- Vol. 18 (6) , 101064
Using mobile technology to increase adherence to sublingual immunotherapy: Real-world study with a new app/web platform AllergyVax®
- 12 May 2025
- Published by Elsevier in World Allergy Organization Journal
- Vol. 18 (6) , 101064
Open AccessUsing mobile technology to increase adherence to sublingual immunotherapy: Real-world study with a new app/web platform AllergyVax®
- Open Access
- 24 January 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
Long-term sublingual bacterial immunotherapy prevents ear, nose and throat infections: A real-life study
Objective: Bacterial extracts have been used for many years to prevent airway infections. Recent findings suggest that immunity can be trained by inducing an immunological memory in both the innate and acquired immune response. This real-life observational study investigated the potential of sublingual bacterial immunotherapy in the prevention of ear, nose, and throat infections. Methods: Patients received sublingual bacterial immunotherapy for 12 months and were followed for 24 months. The number of ear, nose, and throat infection episodes from the previous year was recorded during the initial visit based on the patient’s clinical history. Patients were then followed up with visits every 2 months, and the occurrence of ear, nose, and throat infection episodes was documented at 6, 12, 18, and 24 months after the start of the study. Results: The results demonstrated a strong potential for preventing ear, nose, and throat infections, with a reduction in the number of episodes by 75.68%, 82.27%, 82.78%, and 89.88% at 6, 12, 18, and 24 months, respectively. No adverse effects related to sublingual bacterial immunotherapy administration were reported. Conclusion: The results suggested that long-term sublingual bacterial immunotherapy is safe and effectively prevents ear, nose, and throat infections, even after treatment ends.
- 24 January 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
Open AccessLong-term sublingual bacterial immunotherapy prevents ear, nose and throat infections: A real-life study
Objective: Bacterial extracts have been used for many years to prevent airway infections. Recent findings suggest that immunity can be trained by inducing an immunological memory in both the innate and acquired immune response. This real-life observational study investigated the potential of sublingual bacterial immunotherapy in the prevention of ear, nose, and throat infections. Methods: Patients received sublingual bacterial immunotherapy for 12 months and were followed for 24 months. The number of ear, nose, and throat infection episodes from the previous year was recorded during the initial visit based on the patient’s clinical history. Patients were then followed up with visits every 2 months, and the occurrence of ear, nose, and throat infection episodes was documented at 6, 12, 18, and 24 months after the start of the study. Results: The results demonstrated a strong potential for preventing ear, nose, and throat infections, with a reduction in the number of episodes by 75.68%, 82.27%, 82.78%, and 89.88% at 6, 12, 18, and 24 months, respectively. No adverse effects related to sublingual bacterial immunotherapy administration were reported. Conclusion: The results suggested that long-term sublingual bacterial immunotherapy is safe and effectively prevents ear, nose, and throat infections, even after treatment ends.
- Open Access
- 7 September 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (1) , 101500
V Brazilian Consensus on Rhinitis – 2024
- 7 September 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (1) , 101500
Open AccessV Brazilian Consensus on Rhinitis – 2024
- Open Access
- 18 May 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 3 (3) , 100281
Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI)
- 18 May 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 3 (3) , 100281
Open AccessTransition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI)
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (11) , e024D7011
Brazilian guidelines for allergen immunotherapy in the treatment of allergic asthma
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (11) , e024D7011
Open AccessBrazilian guidelines for allergen immunotherapy in the treatment of allergic asthma
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (5) , e2023D695
Brazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis
Epidemiological studies show that allergic rhinitis (AR) is observed in 10–40% of the world's population. This disease significantly compromises the quality of life, impairing development in children and professional activities in adults. AR is also frequently associated with allergic asthma (AA)1 1 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. https://doi.org/10.1016/j.jaci.2017.03.050 https://doi.org/10.1016/j.jaci.2017.03.0... ,2 2 Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. https://doi.org/10.1016/j.jaci.2020.07.007 https://doi.org/10.1016/j.jaci.2020.07.0... . It has been observed that 15–38% of patients with AR develop concomitant AA. This relationship between AR and AA is based on robust pathophysiological mechanisms, which are consistent with the united airways theory. This model states that environmental exposure to allergenic molecules in genetically predisposed individuals directs the production of specific cytokines responsible for the development of the allergic inflammatory process in the nasal mucosa and lungs1 1 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. https://doi.org/10.1016/j.jaci.2017.03.050 https://doi.org/10.1016/j.jaci.2017.03.0... ,3 3 Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;2010(12):CD002893. https://doi.org/10.1002/14651858.CD002893.pub2 https://doi.org/10.1002/14651858.CD00289... .
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (5) , e2023D695
Open AccessBrazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis
Epidemiological studies show that allergic rhinitis (AR) is observed in 10–40% of the world's population. This disease significantly compromises the quality of life, impairing development in children and professional activities in adults. AR is also frequently associated with allergic asthma (AA)1 1 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. https://doi.org/10.1016/j.jaci.2017.03.050 https://doi.org/10.1016/j.jaci.2017.03.0... ,2 2 Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. https://doi.org/10.1016/j.jaci.2020.07.007 https://doi.org/10.1016/j.jaci.2020.07.0... . It has been observed that 15–38% of patients with AR develop concomitant AA. This relationship between AR and AA is based on robust pathophysiological mechanisms, which are consistent with the united airways theory. This model states that environmental exposure to allergenic molecules in genetically predisposed individuals directs the production of specific cytokines responsible for the development of the allergic inflammatory process in the nasal mucosa and lungs1 1 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. https://doi.org/10.1016/j.jaci.2017.03.050 https://doi.org/10.1016/j.jaci.2017.03.0... ,3 3 Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;2010(12):CD002893. https://doi.org/10.1002/14651858.CD002893.pub2 https://doi.org/10.1002/14651858.CD00289... .
- Open Access
- 15 November 2022
- Published by Maad Rayan Publishing Company in Journal of lasers in medical sciences
- Vol. 13, e48
Bone Neoformation Induced by Low-Level Laser and Methylene Blue Suggests Early Ossification in Rats
Introduction: Bone healing depends on inflammation control and tissue repair time. Low-level laser therapy (LLLT) has been investigated to accelerate this process. Methylene blue (MB), together with LLLT, has been investigated for its antioxidant and anti-inflammatory potential; however, the effects of photosensitizers (photodynamic therapy, PDT) are controversial. This study aimed to verify whether the combination of MB and LLLT changes the course of the consolidation of experimental bone defects. Methods: Sixteen Wistar rats underwent femoral bone defects. In the control group (n=4), LLLT simulations were performed without MB. The MB group (n=4) received MB and simulation of LLLT. The LLLT group (n=4) was exposed to LLLT. The PDT+LLLT group (n=4) received MB and LLLT. At the end of 7 or 14 days, the animals were euthanized, and samples were collected. Results: PDT and LLLT induced osteogenic formation with cellularity (after seven days) and union of bony edges (14 days). On the seventh day, LLLT combined with PDT induced an increase (P<0.05) of 484% in the area of bone neoformation compared to the control. On the fourteenth day, LLLT combined with PDT or alone increased (P<0.05) the area of bone neoformation by 214% and 240% respectively, compared to the control group. The PDT/LLLT combination was associated with increased radiopacity (P<0.038). Conclusion: The combined use of MB with LLLT initiated during the transoperative phase may stimulate the bone repair process in rats.
- 15 November 2022
- Published by Maad Rayan Publishing Company in Journal of lasers in medical sciences
- Vol. 13, e48
Open AccessBone Neoformation Induced by Low-Level Laser and Methylene Blue Suggests Early Ossification in Rats
Introduction: Bone healing depends on inflammation control and tissue repair time. Low-level laser therapy (LLLT) has been investigated to accelerate this process. Methylene blue (MB), together with LLLT, has been investigated for its antioxidant and anti-inflammatory potential; however, the effects of photosensitizers (photodynamic therapy, PDT) are controversial. This study aimed to verify whether the combination of MB and LLLT changes the course of the consolidation of experimental bone defects. Methods: Sixteen Wistar rats underwent femoral bone defects. In the control group (n=4), LLLT simulations were performed without MB. The MB group (n=4) received MB and simulation of LLLT. The LLLT group (n=4) was exposed to LLLT. The PDT+LLLT group (n=4) received MB and LLLT. At the end of 7 or 14 days, the animals were euthanized, and samples were collected. Results: PDT and LLLT induced osteogenic formation with cellularity (after seven days) and union of bony edges (14 days). On the seventh day, LLLT combined with PDT induced an increase (P<0.05) of 484% in the area of bone neoformation compared to the control. On the fourteenth day, LLLT combined with PDT or alone increased (P<0.05) the area of bone neoformation by 214% and 240% respectively, compared to the control group. The PDT/LLLT combination was associated with increased radiopacity (P<0.038). Conclusion: The combined use of MB with LLLT initiated during the transoperative phase may stimulate the bone repair process in rats.